Evidence map›Paper›PMID 39159059›Full record

ArticleBioconjugate chemistry2024

Synthesis of Amphiphilic Amino Poly-Amido-Saccharide and Poly(lactic) Acid Block Copolymers and Fabrication of Paclitaxel-Loaded Mucoadhesive Nanoparticles.

Robert C Sabatelle, Abraham Geller, Siyuan Li, Audrey Van Heest, Uma M Sachdeva, Eric Bressler, Jenny Korunes-Miller, Bassel Tfayli, Aya Tal-Mason, Hussein Kharroubi and 2 more

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Formulation andCurrent pharmaceutical design · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Robert C SabatelleBoston University, Departments of Chemistry and Biomedical Engineering, Boston, Massachusetts 02215, United States.
Abraham GellerDivision of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Siyuan LiBoston University, Departments of Chemistry and Biomedical Engineering, Boston, Massachusetts 02215, United States.
Audrey Van HeestBoston University, Departments of Chemistry and Biomedical Engineering, Boston, Massachusetts 02215, United States.ORCID 0000-0002-5340-838X
Uma M SachdevaDivision of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Eric BresslerBoston University, Departments of Chemistry and Biomedical Engineering, Boston, Massachusetts 02215, United States.
Jenny Korunes-MillerBoston University, Departments of Chemistry and Biomedical Engineering, Boston, Massachusetts 02215, United States.
Bassel TfayliDivision of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Aya Tal-MasonDivision of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Hussein KharroubiDivision of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Yolonda L ColsonDivision of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.
Mark W GrinstaffBoston University, Departments of Chemistry and Biomedical Engineering, Boston, Massachusetts 02215, United States.ORCID 0000-0002-5453-3668

Funding

The Harvard Clinical and Translational Science CenterUL1TR002541 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2018 to 2022
$93.0M
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Ramnik J Xavier · 1991 to 2026
$35.3M
Transgenic CoreP30DK057521 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI BROWN, DENNIS · 2000 to 2019
$31.4M
P&F programP30DK135043 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Dennis Brown · 2023 to 2026
$5.4M
Translational Research in BiomaterialsT32EB006359 · NIBIB · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI MARK W. GRINSTAFF, Michelle H Teplensky · 2009 to 2026
$4.2M
OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADINGFOR TREATING MESOTHELIOMAR01CA232056 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI COLSON, YOLONDA L, GRINSTAFF, MARK W. · 2019 to 2023
$2.7M
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCER01CA227433 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI COLSON, YOLONDA L, GRINSTAFF, MARK W. · 2018 to 2022
$2.7M
Synthetic Biology and Biotechnology (SB2) Predoctoral Training ProgramT32GM130546 · NIGMS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI CHEN, CHRISTOPHER S, KHALIL, AHMAD SAMIR · 2019 to 2023
$1.0M
A Zeiss LSM800 confocal microscope with AiryscanS10OD021577 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI BROWN, DENNIS · 2016 to 2016
$374k
Development of a Surgical Drug Delivery System for Enhancement of CAR T Cell ActivityF30CA257566 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI BRESSLER, ERIC · 2021 to 2024
$209k
NCATS NIH HHS UL1 TR002541NCI NIH HHS F30 CA257566NCI NIH HHS R01 CA227433NCI NIH HHS R01 CA232056NIBIB NIH HHS T32 EB006359NIDDK NIH HHS P30 DK043351NIDDK NIH HHS P30 DK057521NIDDK NIH HHS P30 DK135043NIGMS NIH HHS T32 GM130546NIH HHS S10 OD021577
6 · The paper itself

Abstract

Drug delivery to the esophagus through systemic administration remains challenging, as minimal drug reaches the desired target. Local delivery offers the potential for improved efficacy while minimizing off-target toxicities but necessitates bioadhesive properties for mucosal delivery. Herein, we describe the synthesis of two new mucoadhesive amphiphilic copolymers prepared by sequential ring-opening copolymerization or postpolymerization click conjugation. Both strategies yield block copolymers containing a hydrophilic amine-functionalized poly-amido-saccharide and either a hydrophobic alkyl derivatized poly-amido-saccharide or poly(lactic acid), respectively. The latter resulting copolymers readily self-assemble into spherical, ≈200 nm diameter, positively charged mucoadhesive nanoparticles. The NPs entrap ultrahigh levels of paclitaxel via encapsulation of free paclitaxel and paclitaxel conjugated to a biodegradable, biocompatible poly(1,2-glycerol carbonate). Paclitaxel-loaded NPs rapidly enter cells, release paclitaxel, are cytotoxic to esophageal OE33 and OE19 tumor cells in vitro, and, importantly, demonstrate improved mucoadhesion compared to conventional poly(ethylene glycol)-poly(lactic acid) nanoparticles to ex vivo esophageal tissue.

Indexed as

NanoparticlesPaclitaxelPolyestersAnimalsAntineoplastic Agents, PhytogenicCell Line, TumorDrug CarriersHumansPolymersAntineoplastic Agents, PhytogenicDrug CarriersPaclitaxelPolyesterspoly(lactide)Polymers

Identifiers

PMID39159059
PMCPMC11948293

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.